Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 44 articles:
HTML format

Single Articles

    September 2021
  1. ELAMIN YY, Robichaux JP, Carter BW, Altan M, et al
    Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.
    J Clin Oncol. 2021 Sep 22:JCO2101113. doi: 10.1200/JCO.21.01113.
    PubMed     Abstract available

    August 2021
  2. RAMALINGAM SS, Novello S, Guclu SZ, Bentsion D, et al
    Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
    J Clin Oncol. 2021 Aug 26:JCO2003318. doi: 10.1200/JCO.20.03318.
    PubMed     Abstract available

  3. RODRIGUEZ DE DIOS N, Counago F, Murcia-Mejia M, Rico-Oses M, et al
    Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study.
    J Clin Oncol. 2021 Aug 11:JCO2100639. doi: 10.1200/JCO.21.00639.
    PubMed     Abstract available

  4. PARK K, Haura EB, Leighl NB, Mitchell P, et al
    Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
    J Clin Oncol. 2021 Aug 2:JCO2100662. doi: 10.1200/JCO.21.00662.
    PubMed     Abstract available

  5. SHU CA, Cascone T
    What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Aug 2:JCO2101446. doi: 10.1200/JCO.21.01446.

    July 2021
  6. ROTHSCHILD SI, Zippelius A, Eboulet EI, Savic Prince S, et al
    SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    J Clin Oncol. 2021 Jul 12:JCO2100276. doi: 10.1200/JCO.21.00276.
    PubMed     Abstract available

    June 2021
  7. REMON J, Hendriks LEL, Besse B
    Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Jun 8:JCO2100760. doi: 10.1200/JCO.21.00760.

  8. PASSIGLIA F, Cinquini M, Bertolaccini L, Del Re M, et al
    Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2021 Jun 2:JCO2002574. doi: 10.1200/JCO.20.02574.
    PubMed     Abstract available

    April 2021
  9. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50.
    J Clin Oncol. 2021 Apr 19:JCO2100174. doi: 10.1200/JCO.21.00174.
    PubMed     Abstract available

    March 2021
  10. OWONIKOKO TK, Park K, Govindan R, Ready N, et al
    Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
    J Clin Oncol. 2021 Mar 8:JCO2002212. doi: 10.1200/JCO.20.02212.
    PubMed     Abstract available

  11. DERKS JL, Speel EM, Dingemans AC
    Adjuvant Chemotherapy in Patients With Stage I-IIIA Large-Cell Neuroendocrine Carcinoma: Should a Different Approach Be Applied Than for Small-Cell Lung Cancer?
    J Clin Oncol. 2021 Mar 4:JCO2003598. doi: 10.1200/JCO.20.03598.

  12. DZIADZIUSZKO R, Krebs MG, De Braud F, Siena S, et al
    Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Mar 1:JCO2003025. doi: 10.1200/JCO.20.03025.
    PubMed     Abstract available

  13. WAQAR SN, Govindan R
    Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism.
    J Clin Oncol. 2021;39:697-700.

  14. ZHONG WZ, Wang Q, Mao WM, Xu ST, et al
    Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
    J Clin Oncol. 2021;39:713-722.
    PubMed     Abstract available

    February 2021
  15. HANNA NH, Robinson AG, Temin S, Baker S Jr, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
    J Clin Oncol. 2021 Feb 16:JCO2003570. doi: 10.1200/JCO.20.03570.
    PubMed     Abstract available

  16. EWER MS, Tekumalla SH, Walding A, Atuah KN, et al
    Cardiac Safety of Osimertinib: A Review of Data.
    J Clin Oncol. 2021;39:328-337.
    PubMed     Abstract available

    January 2021
  17. BOYER M, Sendur MAN, Rodriguez-Abreu D, Park K, et al
    Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
    J Clin Oncol. 2021 Jan 29:JCO2003579. doi: 10.1200/JCO.20.03579.
    PubMed     Abstract available

  18. DALY ME, Ismaila N, Decker RH, Higgins K, et al
    Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline.
    J Clin Oncol. 2021 Jan 27:JCO2003364. doi: 10.1200/JCO.20.03364.
    PubMed     Abstract available

  19. GYAWALI B, West HJ
    Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.
    J Clin Oncol. 2021;39:175-177.

  20. BORGHAEI H, Gettinger S, Vokes EE, Chow LQM, et al
    Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Jan 15:JCO2001605. doi: 10.1200/JCO.20.01605.
    PubMed     Abstract available

  21. LIU SV, Reck M, Mansfield AS, Mok T, et al
    Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    J Clin Oncol. 2021 Jan 13:JCO2001055. doi: 10.1200/JCO.20.01055.
    PubMed     Abstract available

    December 2020
  22. KENMOTSU H, Niho S, Tsuboi M, Wakabayashi M, et al
    Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206.
    J Clin Oncol. 2020;38:4292-4301.
    PubMed     Abstract available

  23. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    PubMed     Abstract available

    November 2020
  24. GARASSINO MC, Besse B, Torri V
    To Continue or Not to Continue? That Is the Question.
    J Clin Oncol. 2020;38:3830-3832.

  25. LAU YM, Mok TSK
    The More, The Better?
    J Clin Oncol. 2020;38:3581-3583.

  26. ANG E
    Four Women, One Evening.
    J Clin Oncol. 2020;38:3716-3718.

    October 2020
  27. BURNS TF, Borghaei H, Ramalingam SS, Mok TS, et al
    Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
    J Clin Oncol. 2020 Oct 26:JCO2000744. doi: 10.1200/JCO.20.00744.

    Volume-Based Care Regionalization: Pitfalls and Challenges.
    J Clin Oncol. 2020;38:3465-3467.

  29. GOLDBERG SB, Redman MW, Lilenbaum R, Politi K, et al
    Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.
    J Clin Oncol. 2020 Oct 6:JCO2001149. doi: 10.1200/JCO.20.01149.
    PubMed     Abstract available

    September 2020
  30. WATERHOUSE DM, Garon EB, Chandler J, McCleod M, et al
    Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
    J Clin Oncol. 2020 Sep 10:JCO2000131. doi: 10.1200/JCO.20.00131.
    PubMed     Abstract available

    August 2020
  31. ZHOU C, Li X, Wang Q, Gao G, et al
    Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.
    J Clin Oncol. 2020;38:2753-2761.
    PubMed     Abstract available

  32. CAMIDGE DR, Kim HR, Ahn MJ, Yang JCH, et al
    Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
    J Clin Oncol. 2020 Aug 11:JCO2000505. doi: 10.1200/JCO.20.00505.
    PubMed     Abstract available

  33. RUSTHOVEN CG, Camidge DR, Robin TP, Brown PD, et al
    Radiosurgery for Small-Cell Brain Metastases: Challenging the Last Bastion of Preferential Whole-Brain Radiotherapy Delivery.
    J Clin Oncol. 2020 Aug 10:JCO2001823. doi: 10.1200/JCO.20.01823.

  34. FARJAH F, Grau-Sepulveda MV, Gaissert H, Block M, et al
    Volume Pledge is Not Associated with Better Short-Term Outcomes After Lung Cancer Resection.
    J Clin Oncol. 2020 Aug 7:JCO2000329. doi: 10.1200/JCO.20.00329.
    PubMed     Abstract available

    May 2020
  35. RUDIN CM, Awad MM, Navarro A, Gottfried M, et al
    Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
    J Clin Oncol. 2020 May 29:JCO2000793. doi: 10.1200/JCO.20.00793.
    PubMed     Abstract available

  36. RECK M, Wehler T, Orlandi F, Nogami N, et al
    Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 27:JCO1903158. doi: 10.1200/JCO.19.03158.
    PubMed     Abstract available

  37. KENMOTSU H, Yamamoto N, Yamanaka T, Yoshiya K, et al
    Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 14:JCO1902674. doi: 10.1200/JCO.19.02674.
    PubMed     Abstract available

  38. LEVY EB, Fiel MI, Hamilton SR, Kleiner DE, et al
    State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.
    J Clin Oncol. 2020;38:1633-1640.
    PubMed     Abstract available

    March 2020
  39. NORONHA V, Patil VM, Joshi A, Menon N, et al
    Reply to T. Tanaka et al and F. Liang.
    J Clin Oncol. 2020;38:844-846.

  40. LIANG F
    Contradiction Between Stated Statistical Analysis Method and Displayed Survival Curves.
    J Clin Oncol. 2020;38:844.

  41. RAMALINGAM SS, Dahlberg SE
    Reply to N. Hanna et al and L. Xie et al.
    J Clin Oncol. 2020;38:771-772.

  42. HANNA N, Jalal S
    The Case for Maintenance Pemetrexed Plus Bevacizumab.
    J Clin Oncol. 2020;38:770-771.

    January 2020
  43. WU YL, Zhong WZ, Yan HH
    Reply to A. Tateishi et al.
    J Clin Oncol. 2020;38:286-287.

  44. TATEISHI A, Ishiki H, Kubo E, Satomi E, et al
    EMERGING-CTONG 1103: For Achieving High-Quality Evidence in a Randomized Phase II Trial.
    J Clin Oncol. 2020;38:285-286.

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.